clazakizumab vs. placebo - covid-19 infection

Conditions: COVID-19 Infection

Summary: the purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance). we are proposing to try this drug to treat coronavirus disease 2019 (covid-19) infection. patients with covid-19 infection have been shown to have increases in certain inflammatory processes. clazakizumab is an antibody (immune system protein) that blocks certain inflammatory processes. the treatment plan is to attempt to inhibit or block these inflammatory processes in order to try to limit the damage covid-19 causes to the lungs.

the purpose of this randomized, double-blind, placebo-controlled trial is to evaluate the safety and efficacy of clazakizumab vs placebo for the prevention of acute respiratory distress syndrome (ards) in patients with covid-19 and pulmonary manifestations. the study will compare clazakizumab to placebo in a randomized, double-blind fashion followed by an open-label dose of clazakizumab if there is no improvement or a worsening of condition occurs after 24-hours or anytime during the first 14 days after the first dose of clazakizumab or placebo. we hypothesize that clazakizumab will be safely tolerated and will reduce the risk of progression of covid-19 to acute respiratory distress syndrome. primary objective: • to evaluate the safety and tolerability of clazakizumab vs placebo for the treatment of patients with covid-19 disease and signs of pulmonary involvement sixty adult patients with covid-19 and signs of pulmonary involvement at houston methodist who are not in need of ventilator support at the time of enrollment.

Eligibility criteria:
inclusion criteria: 1. age \>18 at the time of screening. 2. participant or legally authorized representative (lar) must be able to understand and provide informed consent. 3. hospitalized with coronavirus disease (covid-19) confirmed by polymerase chain reaction (pcr) assay from any specimen (eg, respiratory, blood, urine, stool, other bodily fluid) within the prior 72 hours. 4. c-reactive protein (crp) \> 3.5 mg/dl 5. evidence of pulmonary involvement with at least 2 of the following: 1. oxygen saturation at rest in ambient air with peripheral capillary oxygen saturation (spo2) ≤ 94% 2. tachypnea with resting respiration rate \> 25 breaths/minute 3. partial pressure of oxygen (pao2)/initial fraction of inspired oxygen (fio2) ≤ 300 mmhg 4. chest imaging (radiograph, ct, or ultrasound) with abnormalities consistent covid-19 pneumonia exclusion criteria: 1. previous hypersensitivity or allergic reactions to clazakizumab 2. lactating or pregnant females 3. patients with latent tuberculosis (tb) and who are not receiving treatment 4. patients with active tb 5. patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation 6. requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 7. a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count \ 5 times upper limit normal 8. participation in another clinical trial investigating covid-19-aimed agents 9. presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.

Keywords: covid-19 coronavirus infection respiration, artificial extracorporeal membrane oxygenation randomized controlled trial respiratory distress syndrome, adult